Loading
VitsGen Therapeutics is a Chinese company making radioactive medicines that home in on proteins found on tumours. Its lead, 177Lu-FAP-VG11, targets FAP in the tissue around tumours and has orphan drug status for soft tissue sarcoma.
VitsGen says it has developed targeted radiopharmaceuticals since 2021, with teams in China and the United States, and lists FAP, PSMA and carbonic anhydrase IX (CA9) programmes. The FDA record gives the address of VitsGen Therapeutics Inc. in the economic development zone of Tengzhou, Zaozhuang, Shandong. Its lead, 177Lu-FAP-VG11, is the FAP-targeting ligand FAP-VG11 chelated to lutetium-177. China's NMPA Center for Drug Evaluation accepted an IND application for it from Shandong VitsGen Pharmaceutical Co., Ltd. on 12 August 2026, and an investigator-initiated trial at Shandong Cancer Hospital and Institute (NCT07808177) began in September 2026. On 22 October 2026 the FDA granted orphan drug designation for soft tissue sarcoma.
177Lu-FAP-VG11 is an experimental radioactive medicine from VitsGen Therapeutics that targets FAP, a protein on the support cells around many tumours. It is in an early hospital-led trial in China, and the FDA has given it orphan drug status for soft tissue sarcoma.
Shares FAP, Radioligand therapy (beta emitters).
Shares FAP, Radioligand therapy (beta emitters).
Shares Lutetium-177 radioligand therapy, Radioligand therapy (beta emitters).
Shares Lutetium-177 radioligand therapy, Radioligand therapy (beta emitters).
Shares FAP, Radioligand therapy (beta emitters), Sarcomas (soft tissue, bone, GIST).
Shares Lutetium-177 radioligand therapy, Radioligand therapy (beta emitters).
Shares Lutetium-177 radioligand therapy, Radioligand therapy (beta emitters).
Shares FAP, Radioligand therapy (beta emitters), Sarcomas (soft tissue, bone, GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/